Trials / Completed
CompletedNCT06722417
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Icalcaprant in Healthy Adult Japanese and Han Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icalcaprant | Oral capsules |
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2025-01-17
- Completion
- 2025-01-17
- First posted
- 2024-12-09
- Last updated
- 2025-01-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06722417. Inclusion in this directory is not an endorsement.